血清miR-221联合过氧化物还原酶3水平对晚期三阴性乳腺癌患者预后的预测价值  

Predictive value of serum miR-221 combined with peroxiredoxin 3 in patients with advanced triple negative breast cancer

作　　者：刘文志[1] 王振龙[1] 张淼 魏健彪 LIU Wenzhi;WANG Zhenlong;ZHANG Miao;WEI Jianbiao(The First Department of Breast Surgery,Jilin Cancer Hospital,Jilin Province,Changchun 130012,China;The First Department of Radiation Therapy,Jilin Cancer Hospital,Jilin Province,Changchun 130012,China;The Fifth Department of Internal Medicine(Lymph and Blood),Jilin Cancer Hospital,Jilin Province,Changchun 130012,China)

机构地区：[1]吉林省肿瘤医院乳腺外一科,吉林长春130012 [2]吉林省肿瘤医院放疗一科,吉林长春130012 [3]吉林省肿瘤医院内五科(淋巴血液),吉林长春130012

出　　处：《妇儿健康导刊》2025年第3期102-106,共5页JOURNAL OF WOMEN AND CHILDREN'S HEALTH GUIDE

摘　　要：目的探讨血清微小RNA-221(miR-221)联合过氧化物还原酶3(PRX3)水平对晚期三阴性乳腺癌(TNBC)患者预后的预测价值。方法选取2021年1月至2022年1月吉林省肿瘤医院收治的78例晚期TNBC患者为TNBC组,另选取同期50例乳腺良性病变患者为对照组,均采用实时荧光定量聚合酶链式反应检测血清miR-221及PRX3水平并进行比较。对晚期TNBC患者连续随访2年,根据预后情况分为存活组(n=48)与死亡组(n=30),比较不同预后患者血清miR-221及PRX3水平。采用受试者工作特征(ROC)曲线分析血清miR-221及PRX3水平对晚期TNBC患者预后的预测价值。结果TNBC组血清miR-221及PRX3水平均高于对照组(P<0.05)。TNM分期Ⅳb期患者血清miR-221及PRX3水平高于Ⅳa期患者,远处转移数目≥2个患者血清miR-221及PRX3水平高于单发患者(P<0.05);不同年龄TNBC患者血清miR-221及PRX3水平比较,差异无统计学意义(P>0.05)。死亡组血清miR-221及PRX3水平均高于存活组(P<0.05)。ROC曲线分析显示,血清miR-221及PRX3联合检测对晚期TNBC患者预后预测的曲线下面积为0.987,预测灵敏度、特异度分别为93.3%、93.7%,均高于各项指标单独检测(P<0.05)。结论血清miR-221及PRX3水平对晚期TNBC患者预后均具有一定的预测价值,且联合应用预测效能更高,可作为晚期TNBC患者预后评估的敏感指标。Objective To investigate the predictive value of serum micro RNA-221(miR-221)combined with peroxiredoxin 3(PRX3)in patients with advanced triple negative breast cancer(TNBC).Methods A total of 78 patients with advanced TNBC admitted to Jilin Cancer Hospital from January 2021 to January 2022 were selected as the TNBC group,and 50 patients with benign breast lesions were selected as the control group.The levels of serum miR-221 and PRX3 were detected by real-time fluorescent quantitative polymerase chain reaction and compared.Patients with advanced TNBC were followed up for 2 years and divided into the survival group(n=48)and the death group(n=30)according to prognosis.The levels of serum miR-221 and PRX3 in patients with different prognosis were compared.The predictive value of serum miR-221 and PRX3 levels in patients with advanced TNBC was analyzed by receiver operating characteristic(ROC)curve.Results The levels of serum miR-221 and PRX3 in the TNBC group were higher than those in the control group(P<0.05).The levels of serum miR-221 and PRX3 in patients with TNM stageⅣb were higher than those in patients with stageⅣa,and the levels of serum miR-221 and PRX3 in patients with≥2 distant metastases were higher than those in patients with single disease(P<0.05).There were no statistically significant differences in the levels of serum miR-221 and PRX3 in patients with advanced TNBC of different ages(P>0.05).The levels of serum miR-221 and PRX3 in the death group were higher than those in the survival group(P<0.05).ROC curve analysis showed that the area under the curve of serum miR-221 and PRX3 combined detection for predicting the prognosis of patients with advanced TNBC was 0.987,and the predictive sensitivity and specificity were 93.3%and 93.7%,respectively,which were higher than the detection of each indicat or alone(P<0.05).Conclusion The levels of serum miR-221 and PRX3 have certain predictive value for the prognosis of patients with advanced TNBC,and the combined application has higher diagnostic effic

关 键 词：晚期三阴性乳腺癌 血清微小RNA-221 过氧化物还原酶3 预后 

分 类 号：R446.1[医药卫生—诊断学]